Literature DB >> 9588722

Therapeutic node dissections in malignant melanoma.

C P Karakousis1.   

Abstract

In the absence of distant disease, therapeutic node dissections in malignant melanoma, i.e., dissections of regional nodal basins for palpable suspicious or biopsy-proven positive nodes, offer the chance of cure. The 5-year survival rates after therapeutic lymphadenectomy closely correlate with expected cure rates. Although they varied greatly in the literature, from 19% to 38%, the currently obtainable survival rates are in the upper ranges of this spectrum because patients now are closely followed-up and operated for early palpable nodal disease. Properly done, these procedures carry a low morbidity, but they should be done thoroughly to completely eradicate regional disease and avoid recurrences in the same nodal basin to achieve the maximum survival that is surgically attainable.

Entities:  

Mesh:

Year:  1998        PMID: 9588722     DOI: 10.1002/(sici)1098-2388(199806)14:4<291::aid-ssu5>3.0.co;2-y

Source DB:  PubMed          Journal:  Semin Surg Oncol        ISSN: 1098-2388


  5 in total

Review 1.  Multidisciplinary management of special melanoma situations: oligometastatic disease and bulky nodal sites.

Authors:  Amod A Sarnaik; Jonathan S Zager; Vernon K Sondak
Journal:  Curr Oncol Rep       Date:  2007-09       Impact factor: 5.075

Review 2.  [Cutaneous malignant melanoma. Excision margins and lymph node dissections].

Authors:  G Sebastian
Journal:  Hautarzt       Date:  2006-09       Impact factor: 0.751

3.  Dominant lymph drainage in the upper extremity and upper trunk region: evaluation of lymph drainage in patients with skin melanomas.

Authors:  Toshihiko Hayashi; Hiroshi Furukawa; Akihiko Oyama; Emi Funayama; Akira Saito; Yuhei Yamamoto
Journal:  Int J Clin Oncol       Date:  2012-12-08       Impact factor: 3.402

4.  Multimarker reverse transcriptase-polymerase chain reaction assay in lymphatic drainage and sentinel node tumor burden.

Authors:  Piotr Rutkowski; Zbigniew I Nowecki; Alexander C J van Akkooi; Jadwiga Kulik; Michej Wanda; Janusz A Siedlecki; Alexander M M Eggermont; Wlodzimierz Ruka
Journal:  Ann Surg Oncol       Date:  2010-07-07       Impact factor: 5.344

5.  Molecular alterations in clinical stage III cutaneous melanoma: Correlation with clinicopathological features and patient outcome.

Authors:  Piotr Rutkowski; Aleksandra Gos; Monika Jurkowska; Tomasz Switaj; Wirginiusz Dziewirski; Marcin Zdzienicki; Konrad Ptaszyński; Wanda Michej; Andrzej Tysarowski; Janusz A Siedlecki
Journal:  Oncol Lett       Date:  2014-05-08       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.